Analyst Price Target is $17.33
▲ +273.56% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Zura Bio in the last 3 months. The average price target is $17.33, with a high forecast of $26.00 and a low forecast of $5.00. The average price target represents a 273.56% upside from the last price of $4.64.
Current Consensus is
Moderate Buy
The current consensus among 4 polled investment analysts is to moderate buy stock in Zura Bio. This Moderate Buy consensus rating has held steady for over two years.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Read More